Noriaki Yoshida


Department of Clinical Studies


Dr. Yoshida was hired by RERF in April 2018 as an associate senior scientist. After completing his initial clinical training, he worked as a hematologist at a hospital in Hiroshima City, and then engaged in molecular research at Aichi Cancer Center and pathological research at Kurume University. He worked as a postdoctoral fellow at the Dana-Farber Cancer Institute in the U.S. from 2015 to his appointment with RERF. He conducted genomic alteration and molecular function analyses of hematopoietic malignancies such as adult T-cell lymphoma/leukemia, which is common in Japan, to elucidate their clinical significance and identify alterations as potential therapeutic targets. His current research interest is to elucidate pathogenesis of hematopoietic malignancies in A-bomb survivors from a molecular perspective. As the Clinical Laboratories Division Chief, he is committed to providing appropriate test results of health examinations so that the results can be used to promote the health of examinees.


Doctor of Philosophy, Cancer Genetics, Nagoya University School of Medicine, Nagoya, Aichi, Japan
Doctor of Medicine, Miyazaki University School of Medicine, Miyazaki, Japan


Radiation Effects Research Foundation, Department of Clinical Studies
  • 2020-

    Chief, Division of Clinical Laboratories

  • 2018-

    Associate Senior Scientist

Kurume University School of Medicine, Department of Pathology, Kurume, Fukuoka
  • 2018-

    Associate professor/Lecturer

  • 2014-2015

    Assistant professor

Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, Massachusetts, USA
  • 2016-2018

    Overseas Research Fellow, Japan Society for the Promotion of Science

  • 2015-2018

    Postdoctoral Fellow

Aichi Cancer Center, Division of Molecular Medicine, Nagoya, Aichi, Japan
  • 2014-2015

    Research Fellowship for Young Scientist (DC2), Japan Society for the promotion of Science

  • 2011-2015

    Post graduate student, Nagoya University School of Medicine at Aichi Cancer Center Research Institute

Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital, Hiroshima, Japan
  • 2009-2011

    Physician, Department of Hematology

Hiroshima City Asa Hospital, Hiroshima, Japan
  • 2008

    Physician, Department of Hematology

Hiroshima University Hospital, Hiroshima, Japan
  • 2006-2008



Fujihara M, Sakata R, Yoshida N, Ozasa K, Preston DL, Mabuchi K. Incidence of lymphoid neoplasms among atomic bomb survivors by histological subtype: 1950-1994. Blood. 2021; in Press.
Yoshida N, Shigemori K, Donaldson N, Cordero NA, Stevenson KE, Bu X, Arakawa F, Takeuchi M, Ohshima K, Yoda A, Ng SY, Weinstock DM. Genomic landscape of young ATLL patients identifies frequent targetable CD28 fusions. Blood. 2020; 135(17): 1467-71.
Yoshida K, French B, Yoshida N, Hida A, Ohishi W, Kusunoki Y. Radiation exposure and longitudinal changes in peripheral monocytes over 50 years: the Adult Health Study of atomic-bomb survivors. Br J Haematol. 2019; 185(1): 107-15.
Ng SY*, Yoshida N*, Christie AL, Ghandi M, Dharia NV, Dempster J, Murakami M, Shigemori K, Morrow SN, Scoyk AV, Cordero NA, Stevenson KE, Puligandla M, Haas B, Lo C, Meyers R, Gao G, Cherniack A, Louissaint A JR, Nardi V, Thorner AR, Long H, Qiu X, Morgan EA, Dorfman DM, Fiore D, Jang J, Epstein AL, Dogan A, Zhang Y, Horwitz SM, Jacobsen ED, Santiago S, Ren J, Guerlavais V, Annis DA, Aivado M, Tsherniak A, Root D, Vazquez F, Hahn W, Inghirami G, Aster JC, Weinstock DM*, Koch R* *These authors equally contributed. Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nat Commun. 2018; 22; 9(1): 2024.
Kasugai-Maeda Y, Yoshida N, Karube K, Ohshima K, Seto M, Tsuzuki S. A new mouse model of acute ATL generated by transplanting in vitro-induced T cells transduced with AKT, BCLxL and HTLV-1-encoded HBZ. Cancer Sci. 2016; 107(8): 1072-8.
Yoshida N, Miyoshi H, Kato T, Sakata-Yanagimoto M, Niino D, Taniguchi H, Moriuchi Y, Miyahara M, Kurita D, Sasaki Y, Shimono J, Kawamoto K, Utsunomiya A, Imaizumi Y, Seto M, Ohshima K. CCR4 frameshift mutation identifies a distinct group of adult T-cell leukemia/lymphoma with poor prognosis. J Pathol. 2016: 238(5): 621-6.
Yoshida N, Tsuzuki S, Karube K, Takahara T, Suguro M, Nishikori M, Shimoyama M, Tsukasaki K, Ohshima K, Seto M. STX11 functions as a tumor suppressor gene for peripheral T-cell lymphomas. Cancer Sci. 2015; 106(10): 1455-62.
Yoshida N, Karube K, Utsunimiya A, Tsukasaki K, Imaizumi Y, Taira N, Uike N, Umino A, Arita K, Suguro M, Tsuzuki S, Kinoshita T, Ohshima K, Seto M. Molecular characterization of chronic-type adult T-cell leukemia/lymphoma. Cancer Res. 2014; 74(21): 6129-38.
Yoshida N, Oda M, Kuroda Y, Katayama Y, Okikawa Y, Masunari T, Fujiwara M, Takashi Nishisaka, Sasaki N, Sadahira Y, Mihara K, Asaoku K, Matsui H, Seto M, Kimura A, Arihiro K, Sakai A. Clinical significance of sIL-2R levels in B-cell lymphomas. PLOS one. 2013; 8(11): e78730.
Yoshida N, Nishikori M, Izumi T, Imaizumi Y, Sawayama Y, Niino D, Tashima M, Hoshi S, Ohshima K, Shimoyama M, Seto M, Tsukasaki K. Primary peripheral T-cell lymphoma, not otherwise specified of the thyroid with autoimmune thyroiditis. Br J Haematol. 2013; 161(2): 214-23.